Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy

Acta Cardiologica

Volumn 53, Issue 4, 1998, Pages 201-209

  Athyros, Vasilios G ^a,c   Didangelos, Triantaffilos P ^a   Karamitsos, Dimitrios T ^a   Papageorgiou, Athanasios A ^a   Boudoulas, Harisios ^b   Kontopoulos, Athanasios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b OHIO STATE UNIVERSITY   (United States)

^c NONE   (Greece)

Author keywords

Circadian variation of heart rate variability; Diabetic autonomic neuropathy; Quinapril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CHOLINERGIC ACTIVITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODULATION; PATHOGENESIS; SUDDEN DEATH; SYMPATHETIC TONE; VAGUS TONE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIABETIC NEUROPATHIES; FEMALE; HEART RATE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; PARASYMPATHETIC NERVOUS SYSTEM; PROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM; TETRAHYDROISOQUINOLINES;

EID: 0032409046     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Quyyumi AA. Circadian rhythms in cardiovascular disease. Am Heart J 1990; 120: 726-733.
2. Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of R-R variability to predict mortality after myocardial infarction. Circulation 1993; 88: 927-934.
3. Lampert R, Rosenfeld L, Batsford W, Lee F, McPherson C. Circadian variation of sustained ventricular tachycardia in patients with coronary artery disease and implantable cardioverter-defibrillators. Circulation 1994; 90: 241-247.
4. Arntz HR, Willich SN, Oeff M, Bruggemann T, Stern R, Heinzmann A, Matenaer B, Schroder R. Circadian variation of sudden cardiac death reflects age-related variability in ventricular fibrillation. Circulation 1993; 88: 2284-2289.
5. van Ravenswaaij CMA, Kollee LAA, Hopman JCW, Stoelinga GBA, van Geijn HP. Heart rate variability. Ann Inter Med 1993; 118: 436-447.
6. 1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19-21.
7. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79: 1512-1516.
8. Fava S, Azzopardi J, Muscat HA, Fenech FF. Absence of circadian variation in the onset of acute myocardial infarction in diabetic subjects. Br Heart J 1995; 74: 370-372.
9. Tanaka T, Fujita M, Fudo T, Tamaki S, Nohara R, Sasayama S. Modification of the circadian variation of symptom onset of acute myocardial infarction in diabetes mellitus. Coron Artery Dis 1995; 6: 241-244.
10. Hjalmarson A, Gilpin EA, Nicod P, Dittrich H, Henning H, Engler R, Blacky AR, Smith SC Jr, Ricou F, Ross J Jr. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction. Circulation 1989; 80: 267-275.
11. Bernardi L, Ricordi L, Lazzari P, Soldii P, Calciati A, Ferrari MR, Vandea I, Finardi G, Fratino P. Impaired circadian modulation of sympathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation 1992; 86: 1443-1452.
12. Cripps TR, Malik M, Farell T, Camm AJ. Prognostic value of reduction of heart rate variability after acute myocardial infarction: clinical evaluation of a new analysis method. Br Heart J 1991; 65: 14-19.
13. Quintana M, Storck N, Lindblad, Lindvall K, Ericson M. Heart rate variability as a means of assessing prognosis after acute myocardial infarction. Eur Heart J 1997; 18: 789-797.
14. Klingenheben T, Rapp U, Hohnloser SH. Circadian variation of heart rate variability in postinfarction patients with and without life-threatening ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995; 6: 357-364.
15. Kontopoulos A, Athyros V, Didangelos T, Papageorgiou A, Avramidis M, Mayroudi M, Karamitsos D. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997; 20: 355-361.
16. Moore MV, Jeffcoate WJ, Macdonald IA. Apparent improvement in diabetic autonomic neuropathy induced by captopril. J Hum Hypertens 1987; 1: 161-165.
17. The American Diabetes Association and the American Academy of Neurology. Consensus Statement: Standarized measures in diabetic neuropathy. Diabetes Care 1995; 18 (Suppl 1) 18: 59S-82S.
18. Boudoulas H, Mantzouratos D, Sohn YH, Weissler AM. Left ventricular mass and systolic performance in chronic systemic hypertension. Am J Cardiol 1988; 57: 232-237.
19. Kontopoulos AG, Athyros VG, Papageorgiou AA, Papadopoulos GV, Avramidis MJ, Boudoulas H. Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. Am J Cardiol 1996, 77: 242-246.
20. Lombardi F, Sandrone G, Pernpruner S, Sala R, Garimoldi M, Cerutti S, Baselli G, Pagani M, Malliani A. Heart rate variability as an index of sympathovagal interaction after acute myocardial infarction. Am J Cardiol 1987; 60: 1239-1245.
21. Malliani A, Lombardi F, Pagani M, Cerutti S. Power spectral analysis of cardiovascular variability in patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol 1994; 5: 274-286.
22. Bloomfield DM, Kaufman ES, Bigger JT, Jr., Fleiss J, Rolnitzky L, Steinman R. Passive head-up tilt and actively standing up produce similar overall changes in autonomic balance. Am Heart J 1997; 134: 316-321.
23. Akselrod S, Gordon D, Ubel FA, Shannon DC, Barger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuations: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213: 220-222.
24. Pagani M, Lombardi F, Guzzetti S. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59: 178-183.
25. Somsen GA, Szabo BM, van Veldhuisen DJ, de Milliano PA, de Groot CA, Lie KI. Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart rate variability for the assessment of cardiac sympathetic activity in mild to moderate heart failure. Am Heart J 1997; 134: 456-458.
26. Eckberg DL. Sympathovagal balance: A critical appraisal. Circulation 1997; 96: 3224-3232.
27. Spallone V, Bernardi L, Ricordi L, Soldü P, Maiello MR, Calciati A, Gambardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy. Diabetes 1993; 42: 1745-1752.
28. Murakawa Y, Ajiki K, Usui M, Yamashita T, Oikawa N, Inoue H. Parasympathetic activity is a major modulator of the circadian variability of heart rate in healthy subjects and in patients with coronary artery disease or diabetes mellitus. Am Heart J 1993; 126: 108-114.
29. Vanoli E. Acute ischemia, autonomic reflexes, and ventricular fibrillation. Cardiologia 1994; 39 (Suppl 1): 215-220.
30. De Ferrari GM, Vanoli E, Curcuruto P, Tommasini G, Schwartz PJ. Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. Am Heart J 1992; 124: 883-890.
31. Stein KM, Karagounis LA, Anderson JL, Kligfield P, Lerman BB. Fractal clustering of ventricular ectopy correlates with sympathetic tone preceding ectopic beats. Circulation 1995; 91: 722-727.
32. Osterziehl KJ, Rohring N, Dietz R, Manthey J, Hecht J, Kuber W. Influence of captopril on the arterial baroreceptor reflex in patients with heart failure. Eur Heart J 1988; 9: 1137-1145.
33. Osterziehl KJ, Dietz R, Schmid W, Mikulaschek K, Kuber W. ACE inhibition improves vagal activity in patients with heart failure. Am Heart J 1990; 120: 1120-1129.
34. Campbell BC, Sturani A, Reid JL. Evidence of parasympathetic activity of an angiotensin-converting enzyme inhibitor captopril in normotensive men. Clin Scie 1985; 68: 49-56.
35. Townend JN, West JN, Davies MK, Littler WA. Effect of quinapril on blood pressure and heart rate in congestive heart failure. Am J Cardiol 1992; 69: 1587-1590.
36. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV, Cody RJ. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993; 21: 655-661.
37. Papageorgiou A, Karayiannis A, Athyros V, Douma S, Petidis K, Zamboulis C. Comparative study of efficacy and safety of quinapril vs lisinopril in patients with mild to moderate essential hypertension. Drug Invest 1994; 7: 13-17.
38. Townend JN, Virk SJS, Qiang FX, Lawson N, Bainand RJ, Davies MK. Lymphocyte beta adrenoceptor upregulation and improved cardiac response to adrenergic stimulation following converting enzyme inhibition in congestive heart failure. Eur Heart J 1993; 14: 243-250.
39. Malik RA, Tesfaye S, Thompson SD, Veves A, Sharma AK, Boulton AJM, Ward JD. Endoneural localisation of microvascular damage in human diabetic neuropathy. Diabetologia 1993; 36: 454-459.
40. Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial. Ann Intern Med 1993; 118: 7-11.
41. Cameron NE, Cotter MA, Dines KC, Maxfield EK. Pharmacological manipulation of vascular endothelium function in non-diabetic and streptozotocin-diabetic rats: effects on nerve conduction, hypoxic resistance and endoneural capillarization. Diabetologia 1993; 36: 516-522.
42. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AAF, Greene DA. The role of nitric oxide, aldose reductase and (Na, K) ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94: 853-859.
43. 2) synthesis by aortic rings from rats with streptozotocin-induced diabetes. Prostagl Leukot Essent Fatty Acids 1991; 44: 233-236.
44. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995; 11: 193-225.
45. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-18.
46. Reja A, Tesfaye S, Harris ND, Ward JD. Is ACE inhibition with lisinopril helpful in diabetic neuropathy? Diabetic Med 1995; 12: 307-309.
47. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265.
48. Pozzati A, Pancaldi LG, Di Pasquale G, Pinelli G, Bugiardini R. A transient decrease in heart rate variability in patients with sudden "ischemic" death during Holter monitoring. G Ital Cardiol 1995; 25: 725-732.